I
Immunophage Biotech
An innovative drug discovery company focusing on cancer and autoimmune diseases with unmet medical needs
About Immunophage Biotech
Immunophage is a clinical-stage biotech company dedicated to discovering, developing, and commercializing innovative drugs on a global scale. The company focuses on creating next-generation immunotherapies designed to benefit patients worldwide. Immunophage strengthens its research and development (R&D) pipeline by continuously exploring novel disease mechanisms, refining new targets, and discovering both small and large molecule drugs.
The company aims to advance two innovative programs into clinical trials by leveraging its internal R&D expertise and forming strategic partnerships with global biopharmaceutical companies. Immunophage's medical team integrates seamlessly with clinical practice, prioritizing patient interests and being guided by clinical value. They specialize in innovative and safe drug development strategies, collaborating with clinical researchers from the early stages to maximize the potential of their medications.
The clinical operation team at Immunophage has extensive experience in clinical project management, data management, statistics, pharmacovigilance, and pharmacology. The company serves a diverse range of clients, including global biopharmaceutical companies and clinical researchers. Immunophage operates in the highly competitive biotechnology and pharmaceutical market, focusing on immunotherapy and innovative drug development.
The business model revolves around advancing drug candidates through clinical trials and forming strategic partnerships to commercialize these therapies. Revenue is generated through licensing agreements, partnerships, and eventual sales of approved drugs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Huangpu, China
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 27.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Mar 2023 | $2.9M | — | Undisclosed | ↗ |
| SERIES BOther financing | Mar 2023 | $12M | $46M | Zhongbo Juli | ↗ |
Growth signals
Latest recorded traffic for Immunophage Biotech is 60 monthly website visits, down 83.3% over the last three months. Immunophage Biotech's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Shanghai Junshi Biosciences- NFNew Silk Road Finance
- ZJZhongbo Juli
Other known investors3 additional known investors
Med-Fine Capital- NUNanchang University
Yijing Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immunophage Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immunophage Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.